Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review.

Cureus · 2022 · PMC9547534 · PMID 36237809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might not be significantno p-value reported

This finding is important because it allows them to conclude that genetic analysis might not be significant when assessing the evolocumab response in patients with HeFH [ 17 ].

also in 670 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.